Konstantinos Sdrimas
Hematology & Oncology · Morgantown, WVNPI 1952782534
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $57,330 of the $81,287 with a category attached, or 70.5%. E.r. Squibb & Sons, L.L.C. accounts for 87.0% of it on its own, with 15 other manufacturers making up the rest. 2025 is the largest year on record at $79,225, more than ten times the $1,047 reported in 2019. Among hematology & oncology clinicians in WV with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 102 payments — averaging $796.93 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- E.r. Squibb & Sons, L.L.C.$71K
- Gilead$8K
- Bristol Myers Squibb$492
- AstraZeneca$460
- Seagen Inc.$381
- Legend Biotech USA Inc.$195
- plus $802 from 10 others
Across 10 payments — averaging $6765.00 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Bristol Myers Squibb$63K
- E.r. Squibb & Sons, L.L.C.$4K
What the payments were for
- Consulting fees$8,75511%
- Speaking & faculty fees$57,33071%
- Travel & lodging$11,02214%
- Food & beverage$3,8905%
- Education$2900%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| E.r. Squibb & Sons, L.L.C. | 43 | $70,726 |
| Gilead | 10 | $8,231 |
| Bristol Myers Squibb | 16 | $492 |
| AstraZeneca(2 entities) | 10 | $460 |
| Seagen Inc. | 5 | $381 |
| Legend Biotech USA Inc. | 3 | $195 |
| Lilly USA, LLC | 3 | $128 |
| Genentech USA, Inc. | 1 | $124 |
| Lantheus Medical Imaging, Inc. | 1 | $115 |
| Incyte Corporation | 1 | $100 |
| Amgen | 1 | $95 |
| AMAG Pharmaceuticals, Inc. | 1 | $71 |
| Pfizer | 4 | $65 |
| Beigene USA, Inc. | 1 | $56 |
| Novartis | 1 | $32 |
| Janssen Scientific Affairs, LLC | 1 | $16 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$81,287 in reported general payments places this provider in the 90th percentile of 72 hematology & oncology providers in West Virginia.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Lenalidomide | 51 | $698,110 |
| PomalystPomalidomide | 31 | $692,581 |
| XospataGilteritinib Fumarate | 25 | $652,017 |
| Bexarotene | 12 | $566,008 |
| ImbruvicaIbrutinib | 25 | $400,102 |
| RevlimidLenalidomide | 24 | $392,245 |
| TasignaNilotinib Hcl | 19 | $235,303 |
| CalquenceAcalabrutinib Maleate | 14 | $206,031 |
| VenclextaVenetoclax | 30 | $173,292 |
| NinlaroIxazomib Citrate | 12 | $156,475 |
| SorafenibSorafenib Tosylate | 14 | $127,949 |
| Imatinib Mesylate | 21 | $56,854 |
| EliquisApixaban | 13 | $11,000 |
| Atovaquone | 14 | $5,484 |
| GengrafCyclosporine, Modified | 13 | $1,725 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| E.r. Squibb & Sons, L.L.C.Pomalyst | $70,726 | $692,58131 claims |
| Bristol Myers SquibbRevlimid | $492 | $392,24524 claims |
| NovartisTasigna | $32 | $235,30319 claims |
| AstraZenecaCalquence | $460 | $206,03114 claims |
| PfizerEliquis | $65 | $11,00013 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 72 hematology & oncology providers in West Virginia.
Other hematology & oncology in Morgantown
- Abraham KanateMorgantown$169K
- Ashkan EmadiMorgantown$88K
- Ihtishaam QaziMorgantown$18K
- Sonikpreet AulakhMorgantown$17K
- Salah Ud Din SafiMorgantown$5K
- Michael CraigMorgantown$5K
- Joanna KolodneyMorgantown$3K
- Amir KamranMorgantown$2K
- Sobha KurianMorgantown$1K
- Pooja Gogia BhasinMorgantown$1K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.